| Stage | NDSN | % of rev | ESAB | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $818M | 100.00% | $808M | 100.00% | NDSN ×1.01 |
| Gross profit | $454M | 55.49% | $307M | 38.04% | NDSN +17.5pp |
| Operating income | $223M | 27.28% | $79M | 9.75% | NDSN +17.5pp |
| Pre-tax income | $186M | 22.74% | $48M | 5.96% | NDSN +16.8pp |
| Net income | $153M | 18.69% | $34M | 4.21% | NDSN +14.5pp |
| Stage | NDSN | ESAB | Gap · A − B |
|---|---|---|---|
| Revenue | $818M100.00% | $808M100.00% | NDSN ×1.01 |
| Gross profit | 55.49%$454M | 38.04%$307M | NDSN +17.5pp |
| Operating income | 27.28%$223M | 9.75%$79M | NDSN +17.5pp |
| Pre-tax income | 22.74%$186M | 5.96%$48M | NDSN +16.8pp |
| Net income |
| 18.69%$153M |
| 4.21%$34M |
| NDSN +14.5pp |
None
No disclosed counterparties: NDSN.